Regulation FD Disclosure (Form 8-K)

On February 10, 2026, Nektar Therapeutics (the "Company") announced it had approximately $229.1 million in cash and investments in marketable securities as of January 31, 2026. This announcement reflects the Company's estimates based solely upon information available to it as of the date of the announcement, and the amounts reported are not a comprehensive statement of its operating results or financial position as of January 31, 2026.

The information contained in Item 7.01 of this Current Report on Form 8-Kis being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.